DHR:NYE-Danaher Corporation (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 230.75

Change

+1.59 (+0.69)%

Market Cap

USD 165.08B

Volume

0.99M

Analyst Target

USD 220.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
A Agilent Technologies Inc

+1.50 (+1.11%)

USD 40.09B
IQV IQVIA Holdings Inc

+0.88 (+0.44%)

USD 36.13B
LH Laboratory Corporation of Amer..

+1.65 (+0.72%)

USD 19.12B
DGX Quest Diagnostics Incorporated

+0.48 (+0.31%)

USD 17.09B
QGEN Qiagen NV

+0.24 (+0.54%)

USD 10.26B
CRL Charles River Laboratories

+0.90 (+0.49%)

USD 9.50B
VNRX Volitionrx Ltd

+0.04 (+6.56%)

USD 0.06B
ENZ Enzo Biochem Inc

-0.01 (-1.90%)

USD 0.04B
TMO Thermo Fisher Scientific Inc

+3.69 (+0.70%)

N/A
MTD Mettler-Toledo International I..

+11.91 (+0.96%)

N/A

ETFs Containing DHR

AILG 6.99 % 0.00 %

N/A

N/A
SYNB Putnam Biorevolution ETF 6.29 % 0.00 %

+0.11 (+0.69%)

USD 5.36M
DXSF:XETRA Xtrackers - Stoxx Europe .. 5.91 % 0.00 %

N/A

USD 0.08B
LIFE-U:CA Evolve Global Healthcare .. 5.53 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 4.69 % 0.00 %

+0.27 (+0.69%)

N/A
BCHP EGSHARES BLUE CHIP ETF EG.. 4.47 % 0.00 %

+0.32 (+0.69%)

USD 0.09B
XDG3:XETRA Xtrackers MSCI Global SDG.. 4.45 % 0.00 %

N/A

USD 0.14B
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.34 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 4.21 % 0.00 %

N/A

N/A
YALL God Bless America ETF 4.17 % 0.00 %

+0.52 (+0.69%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.11 % 0.00 %

+0.10 (+0.69%)

N/A
CBUF:F iShares V Public Limited .. 4.06 % 0.00 %

N/A

N/A
SANE 3.95 % 0.00 %

N/A

N/A
GDOC Goldman Sachs ETF Trust 3.52 % 0.00 %

+0.05 (+0.69%)

USD 0.02B
XUHC:SW 3.16 % 0.00 %

N/A

N/A
IUHC:SW iShares S&P 500 Health Ca.. 3.06 % 0.00 %

N/A

N/A
GXLV:LSE SPDR® S&P® U.S. Health .. 3.06 % 0.00 %

+0.31 (+0.69%)

N/A
XLV Health Care Select Sector.. 2.92 % 0.13 %

+0.57 (+0.69%)

USD 36.67B
QDVG:XETRA iShares S&P 500 Health Ca.. 2.90 % 0.00 %

N/A

USD 2.05B
SXLV:SW SPDR S&P U.S. Health Care.. 2.86 % 0.00 %

N/A

N/A
ZPDH:F SPDR S&P U.S. Health Care.. 2.85 % 0.00 %

N/A

USD 0.40B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 2.85 % 0.00 %

N/A

USD 0.40B
XSHC:LSE Xtrackers MSCI USA Health.. 2.85 % 0.00 %

+45.00 (+0.69%)

USD 0.61B
XUHC:LSE Xtrackers MSCI USA Health.. 2.85 % 0.00 %

+0.74 (+0.69%)

USD 0.61B
CNEQ The Alger ETF Trust 2.83 % 0.00 %

+0.26 (+0.69%)

N/A
XUHC:F Xtrackers (IE) Public Lim.. 2.79 % 0.00 %

N/A

USD 0.85B
XUHC:XETRA Xtrackers MSCI USA Health.. 2.79 % 0.00 %

N/A

USD 0.85B
INNO Harbor Disruptive Innovat.. 2.76 % 0.00 %

N/A

N/A
BKDV BNY Mellon ETF Trust II 2.70 % 0.00 %

+0.17 (+0.69%)

USD 0.01B
CURE Direxion Daily Healthcare.. 2.59 % 1.06 %

+1.01 (+0.69%)

USD 0.17B
FHLC Fidelity® MSCI Health Ca.. 2.54 % 0.08 %

+0.15 (+0.69%)

USD 2.62B
WEBD:XETRA AETF-MUSCNZAP EOA ETF 2.50 % 0.00 %

N/A

N/A
USRI:LSE 2.50 % 0.00 %

N/A

N/A
UPVLD:SW 2.35 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.30 % 0.00 %

N/A

N/A
XAMB:F Amundi Index Solutions - .. 1.53 % 0.00 %

N/A

N/A
HYLG Global X Funds - Global X.. 1.44 % 0.00 %

+0.05 (+0.69%)

N/A
LESW:LSE 1.38 % 0.00 %

N/A

N/A
WSRI:LSE 1.30 % 0.00 %

N/A

N/A
WELB:XETRA Amundi MSCI ACWI SRI PAB .. 1.08 % 0.00 %

N/A

N/A
RAVI FlexShares Ready Access V.. 0.86 % 0.25 %

+0.05 (+0.69%)

USD 1.15B
CWW.A:CA 0.00 % 1.49 %

N/A

N/A
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+0.19 (+0.69%)

N/A
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

+0.24 (+0.69%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
JMIN 0.00 % 0.12 %

N/A

N/A
EVSTC 0.00 % 0.00 %

N/A

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.01 (+0.69%)

CAD 0.05B
LS:CA 0.00 % 2.21 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.07 (+0.69%)

N/A
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

+0.23 (+0.69%)

N/A
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+0.84 (+0.69%)

N/A
MIVG:CA Mackenzie Ivy Global Equi.. 0.00 % 0.89 %

+0.30 (+0.69%)

CAD 0.02B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.00 %

+7.50 (+0.69%)

N/A
IUHC:LSE iShares S&P 500 USD Healt.. 0.00 % 0.00 %

+0.11 (+0.69%)

USD 2.50B
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.00 %

+0.51 (+0.69%)

N/A
XDWH:LSE Xtrackers MSCI World Heal.. 0.00 % 0.00 %

+0.53 (+0.69%)

N/A
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.00 %

N/A

N/A
GNAR:F 0.00 % 0.00 %

N/A

N/A
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.00 %

N/A

N/A
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
GNAR:XETRA 0.00 % 0.00 %

N/A

N/A
VMOM:XETRA 0.00 % 0.00 %

N/A

N/A
NUSA:CA NBI Active U.S. Equity ET.. 0.00 % 0.00 %

N/A

CAD 0.07B
XOUT GraniteShares XOUT U.S. L.. 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

+0.19 (+0.69%)

USD 4.16M
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.04 (+0.69%)

N/A
MEDTE:PA BNP Paribas Easy ECPI Glo.. 0.00 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.26% 54% F 37% F
Dividend Return 0.35% 43% F 3% F
Total Return 0.10% 54% F 26% F
Trailing 12 Months  
Capital Gain -0.28% 46% F 37% F
Dividend Return 0.45% 43% F 5% F
Total Return 0.17% 54% F 27% F
Trailing 5 Years  
Capital Gain 70.32% 100% F 81% B-
Dividend Return 3.00% 40% F 8% B-
Total Return 73.32% 100% F 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.29% 46% F 61% D-
Dividend Return 8.66% 46% F 55% F
Total Return 0.37% 43% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 29.49% 46% F 36% F
Risk Adjusted Return 29.37% 46% F 44% F
Market Capitalization 165.08B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.